Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Evaluation of Renal Tumor Diagnostics in Global Pathology Practice.

International journal of surgical pathology·2026

Same author

Enhancing Graduate Surgical Education: Recommendations for Development of Common Surgery Education and Training Accreditation Standards.

Annals of surgery open : perspectives of surgical history, education, and clinical approaches·2026

Same author

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.

Nature medicine·2026

Same author

Salvage lymph node dissection in oligo-recurrent prostate cancer patients: Mapping patterns of recurrence and factors associated with disease progression.

Urologic oncology·2026

Same author

Re: Kitamura et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection (JCOG1019). Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008.

European urology·2026

Same author

Chemotherapy-induced activation of caspase-1 and IL-1α release by cancer cells remotely skews myelopoiesis to drive pro tumorigenic systemic neutrophil-dominant inflammation.

Nature communications·2026

Same journal

Trophoblastic-Differentiated Urothelial Carcinoma: Real-World Sequencing and Clinical Implications.

Clinical genitourinary cancer·2026

Same journal

Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis.

Clinical genitourinary cancer·2026

Same journal

Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature.

Clinical genitourinary cancer·2026

Same journal

Beyond the Hazard Ratio: Time-Varying Treatment Effects in Genitourinary Cancer Trials.

Clinical genitourinary cancer·2026

Same journal

Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma.

Clinical genitourinary cancer·2026

Same journal

Longitudinal Tumor Mutation Burden Dynamics in Advanced Prostate Cancer Using Circulating Tumor DNA Profiling.

Clinical genitourinary cancer·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Aug 30, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Renal Sarcoma: A Population-Based Study.

Michail Alevizakos¹, Apostolos Gaitanidis², Dimitrios Korentzelos³

¹Hematology/Oncology Division, Beth Israel Deaconess Medical Center, Boston, MA.

Clinical Genitourinary Cancer

|August 31, 2022

Summary

This summary is machine-generated.

This study introduces a new 3-stage classification for rare renal sarcomas, improving prognostic accuracy. The novel system shows distinct survival curves, aiding in better patient outcome prediction for this rare cancer.

Keywords:

Epidemiology Renal SEER Sarcoma Staging

More Related Videos

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Related Experiment Videos

Last Updated: Aug 30, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Area of Science:

Oncology
Urologic Oncology
Cancer Research

Background:

Renal sarcomas are rare tumors lacking established prognostic staging.
Accurate staging is crucial for predicting outcomes and guiding treatment in rare cancers.

Purpose of the Study:

To investigate the clinicopathologic characteristics and outcomes of renal sarcomas.
To develop and evaluate a novel prognostic staging system for renal sarcomas.

Main Methods:

Utilized the Surveillance, Epidemiology, and End Results (SEER) database for patient data (2004-2015).
Employed Kaplan-Meier curves for survival analysis and multivariable regression for outcome comparisons.
Developed a 3-stage system based on Tumor Node Metastasis (TNM) criteria.

Main Results:

Identified 365 patients with renal sarcoma; 28.5% stage I, 36.4% stage II, and 32.1% stage III.
Median survival varied significantly by stage: 105 months (Stage I), 46 months (Stage II), and 8 months (Stage III).
Age, advanced stage, higher tumor grade, and lack of insurance were independently associated with poorer overall survival (OS).

Conclusions:

A novel 3-stage classification for renal sarcomas demonstrates distinct survival outcomes.
This TNM-based staging system shows potential for improved prognostic assessment in renal sarcoma patients.
Further research is necessary to validate this new staging system for clinical application.